奥沙利铂联合卡培他滨在Ⅱ～Ⅲ期胃癌术后化疗中的疗效观察

观察奥沙利铂联合卡培他滨对胃癌术后患者的疗效及对T淋巴细胞亚群的影响。方法:将本院自2007年1月至2009年12月间收治的中晚期胃癌术后患者84例，按入院顺序分为观察组和对照组，每组42例。观察组采用奥沙利铂和卡培他滨联合应用的XELOX方案，对照组采用FOLFOX方案。观察两组患者不良反应、1年生存率、无进展生存期等指标。检测化疗前后T淋巴细胞亚群的变化。结果:观察组患者白细胞减少、恶心呕吐等一般化疗反应的发生率显著低于对照组；腹泻和神经毒性的发生率两组之间差异无显著性；观察组手足综合症的发生率显著高于对照组；观察组患者平均化疗（3.93±0.42）个周期，一年生存率为83.3%，无疾病生存期（9.1±2.3）个月，均显著优于对照组；化疗后两组患者CD3+、CD4+细胞的比例以及CD4+/CD8+的比值均较化疗前显著升高，CD4+、CD25+细胞的比例显著下降（P<0.05），观察组患者上述指标变化更显著。结论:对胃癌患者采用奥沙利铂联合卡培他滨化疗方案可显著改善机体的免疫抑制状态，恢复淋巴细胞亚群比例，取得良好的治疗效果。 

Oxaliplatin Combined with Capecitabine as Chemotherapy for Post-operative Patients with Advanced Gastric Carcinoma

To observe the curative effects of oxaliplatin combined with capecitabine on the therapy of post-operative patients with advanced gastric carcinoma and its effects on the lymphocyte subcluster. Methods: A total of 84 post-operative patients with advanced gastric carcinoma from 2007 to 2009 in our hospital were divided into the observation group and the control group based on the sequence of hospitalization. XELOX ( oxaliplatin with capecitabine ) was used in the observation group. FOLFOX was used in the control group. The adverse effects, one-year survival rate, and progression-free survival time were observed. The lymphocyte subcluster was determined. Results: The incidence rates of hypoleukocytosis, nausea, and vomiting in the observation group were significantly lower than those in the control group. The incidence rates of diarrhea and neurovirulence had no differences between these two groups. The incidence of hand and foot syndrome in the observation group was significantly higher than that in the control group. The chemotherapy cycle was 3.93 ± 0.42, with a one-year survival rate of 83.3%, and a progression-free survival time of 9.1 ± 2.3 months in the observation group, which were significantly better than those in the control group. The proportion of CD3+ and CD4+ T cells and the ratio of CD4+/CD8+ were significantly increased and the proportion of CD4+CD25+ T cells were significantly decreased after chemotherapy ( P < 0.05 ). The changes were more significant in the observation group than those in the control group. Conclusion: Oxaliplatin with capecitabine could improve the immunosuppression condition, recovery of the ratio of lymphocyte sub-cluster, and obtain a satisfactory curative effect in postoperative patients with advanced gastric carcinoma.